scholarly journals TCT-666 Safety Evaluation of the Biodegradable Polymer-Based Sirolimus-Eluting Stent with Faster Drug Eluting Rate and Polymer Absorption Kinetics in Complex Patient and Lesion Subgroup of the PANDA III Trial

2018 ◽  
Vol 72 (13) ◽  
pp. B266
Author(s):  
Sida Jia ◽  
Changdong Guan ◽  
Jinqing Yuan ◽  
Runlin Gao ◽  
Martin Leon ◽  
...  
Keyword(s):  
Biodegradable Polymer ◽  
Safety Evaluation ◽  
Absorption Kinetics ◽  
Complex Patient ◽  
Drug Eluting ◽  
Sirolimus Eluting Stent

P2813The improvement of chronic local coagulative response according to the progress of drug eluting stent

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
K Yamaguchi ◽  
T Wakatsuki ◽  
R Ueno ◽  
Y Kawabata ◽  
T Matsuura ◽  
...  
Keyword(s):  
Coronary Sinus ◽  
Biodegradable Polymer ◽  
Coronary Angioplasty ◽  
Plasma Levels ◽  
Drug Eluting Stent ◽  
Sinus Of Valsalva ◽  
Strut Thickness ◽  
Durable Polymer ◽  
Drug Eluting ◽  
Sirolimus Eluting Stent

Abstract Background We have previously reported local persistent hypercoagulation after sirolimus-eluting stent (SES) implantation by measuring local plasma prothrombin fragment 1+2 (F1+2) levels. The aim of this study is to examine chronic local coagulative response after each generation- drug eluting stent (DES) implantation. Methods Ninety-five patients who were treated about eight months earlier with coronary angioplasty, with no evidence of restenosis, were studied [1stgeneration durable polymer (DP)-DES {SES; Cypher®: 26pts, paclitaxel-eluting stent (PES); Taxus®:16pts}, 2ndgeneration DP-DES {everolimus-eluting stent (EES); Xience®:15pts, zotarolimus-eluting stent (ZES); Endeavor®:15pts}, and 3rdgeneration biodegradable polymer (BP)-DES {BP-biolimus-eluting stent (BES); Nobori®: 11pts and BP-SES; Ultimaster®: 12pts}]. We measured plasma levels of F1+2 sampled in coronary sinus (CS) and sinus of Valsalva (V). The transcardiac gradient (Δ) was defined as CS level minus V level. Results No significant differences were observed in the percent diameter stenosis among 1st, 2nd, and 3rd DES groups (12.5±15.5 vs 16.1±12.9 vs 13.1±11.9%). The ΔF1+2 was significantly lower in the 2nd and 3rd DES groups than in the 1st DES group (9.0±15.4 and 10.0±17.4 vs 27.3±23.8pmol/l, p<0.05, respectively). The ΔF1+2 was significantly lower in the BP-DES groups (BP-BES and BP-SES) than in the DP-DES groups (DP-SES, DP-PES, DP-ZES, and DP-EES) (10.0±17.4 vs 18.1±19.5pmol/l, p<0.05). The ΔF1+2 was significantly lower in the thin strut-DES groups (BP-SES, DP-ZES, and DP-EES) than in the thick strut-DES groups (DP-SES, DP-PES, and BP-BES) (8.4±15.4 vs 21.7±18.5pmol/l, p<0.05). In the BP-DES groups, the ΔF1+2 was lower in the BP-SES group than in the BP-BES group (8.0±16.1 vs 12.7±18.1pmol/l, p=0.08). Conclusions The improvement of chronic local coagulative response was observed according to the progress of DES. These findings might be associated with lower strut thickness and faster polymer resorption in the newer-generation DES.

scholarly journals Real World Experience of a Biodegradable Polymer Sirolimus-Eluting Stent (Yukon Choice PC Elite) in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty: A Multicentric Observational Study (The Elite India Study)

2019 ◽  
Vol 7 (7) ◽  
pp. 1103-1109
Author(s):  
Bhupendra Verma ◽  
Akhilesh Patel ◽  
Deepak Katyal ◽  
Vivek Raj Singh ◽  
Avinash Kumar Singh ◽  
...  
Keyword(s):  
Observational Study ◽  
Biodegradable Polymer ◽  
Composite Endpoint ◽  
Primary Angioplasty ◽  
Drug Eluting Stents ◽  
Safety And Efficacy ◽  
Drug Eluting ◽  
Sirolimus Eluting Stent ◽  
One Year

BACKGROUND: The durable polymer drug-eluting stents (DPDES) reduce the risk of repeated target vessel revascularisation (TLR) compared with BMS, but are associated with increased risk of late adverse events. In broadly inclusive populations, the biodegradable-polymer drug-eluting stents (BPDES) have favourable results compared with DPDES in the long term. However, its use in primary angioplasty has not been adequately studied, and data of real-world clinical experience is lacking. AIM: Aim of this study was to assess the safety and efficacy of Yukon Choice PC Elite sirolimus-eluting stent (a novel BPDES) in STEMI patients undergoing primary angioplasty. METHODS: We have presented here one-year clinical follow-up data of the Yukon Choice PC Elite sirolimus-eluting stent in patients undergoing primary angioplasty. A total of 636 patients were enrolled in this single arm, prospective observational study from five centres. RESULTS: This multicentric observational study showed excellent safety and efficacy profile of the novel device at one year follow up. The device-oriented composite endpoint (DOCE) of cardiac death, target-vessel reinfarction, and target-lesion revascularisation (TLR) was 2.7%, and the patient-oriented composite endpoint (POCE) of all-cause death, any myocardial infarction, and any revascularisation was 4.2% at one year. Definite or probable stent thrombosis rate was 0.6%, and no events were recorded beyond 6 months of follow up. CONCLUSIONS: In patients with STEMI undergoing primary angioplasty, the use of Yukon Choice PC Elite (biodegradable polymer sirolimus-eluting stent) has excellent results at one year. It, therefore, represents an attractive alternative to second generation DES in this high-risk population.

Sign in / Sign up

Export Citation Format

Share Document